Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Open access
Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.·2008·Blood

Abstract

The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patients were evaluated at 3, 6, 12, and 18 months and some were classified as “failure” or “suboptimal responders.” We analyzed outcomes for 224 patients with chronic myeloid leukemia in chronic phase treated in a single institution to validate these recommendations. Patients were followed for a median of 46.1 months. At each time point, patients classified as “failure” showed significantly worse survival, progression-free survival, and cytogenetic response than other patients; for example, based on the assessment at 12 months, the 5-year survival was 87.1% versus 95.1% (P = .02), progression-free survival 76.% versus 90% (P = .002), and complete cytogenetic response rate 26.7% versus 94.1% (P < .001). Similarly, the criteria for “suboptimal response” at 6 and 12 months identified patients destined to fare badly, although criteria at 18 months were less useful. The predictive value of some other individual criteria varied. In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories “failure” and “suboptimal response.”

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-06-162388

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 328

Metadata

Authors
Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J. S., de Lavallade, H., Reid, A. G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., Pavlu, J., Klammer, M., Kaeda, J. S., Goldman, J. M., & Apperley, J. F.
Venue
Blood
Published
2008-12-01
Volume
112
Issue
12
Pages
4437-4444
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1980571402
Cited by
328
References
1
FWCI
22.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. https://app.cochat.ai/papers/10.1182/blood-2008-06-162388
The paper
Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J. S., de Lavallade, H., Reid, A. G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., Pavlu, J., Klammer, M., Kaeda, J. S., Goldman, J. M., & Apperley, J. F. (2008). European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. https://doi.org/10.1182/blood-2008-06-162388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.